Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #028
268
mi
from 02139
Norristown, PA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #028
268
mi
from 02139
Norristown, PA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
34
mi
from 02139
Lincoln, RI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
34
mi
from 02139
Lincoln, RI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 001
815
mi
from 02139
North Charleston, SC
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 001
815
mi
from 02139
North Charleston, SC
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
1602
mi
from 02139
Houston, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
1602
mi
from 02139
Houston, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 082
1593
mi
from 02139
Wichita Falls, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 082
1593
mi
from 02139
Wichita Falls, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 111
2094
mi
from 02139
Murray, UT
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 111
2094
mi
from 02139
Murray, UT
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 064
490
mi
from 02139
Charlottesville, VA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 064
490
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 014
2475
mi
from 02139
Bothell, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 014
2475
mi
from 02139
Bothell, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #027
2483
mi
from 02139
Seattle, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #027
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 007
933
mi
from 02139
Middleton, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 007
933
mi
from 02139
Middleton, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 049
853
mi
from 02139
Milwaukee, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 049
853
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 057
869
mi
from 02139
Waukesha, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 057
869
mi
from 02139
Waukesha, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #021
2585
mi
from 02139
Garden Grove, CA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #021
2585
mi
from 02139
Garden Grove, CA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 008
2532
mi
from 02139
Redlands, CA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 008
2532
mi
from 02139
Redlands, CA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 1854
1255
mi
from 02139
Hialeah, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 1854
1255
mi
from 02139
Hialeah, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #005
1249
mi
from 02139
North Miami, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #005
1249
mi
from 02139
North Miami, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 004
1252
mi
from 02139
Overland Park, KA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 004
1252
mi
from 02139
Overland Park, KA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 066
719
mi
from 02139
Mason, OH
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 066
719
mi
from 02139
Mason, OH
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 064
555
mi
from 02139
Middleburg Heights, OH
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 064
555
mi
from 02139
Middleburg Heights, OH
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 014
1683
mi
from 02139
Austin, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 014
1683
mi
from 02139
Austin, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
2474
mi
from 02139
Bellevue, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
2474
mi
from 02139
Bellevue, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 033
1680
mi
from 02139
San Juan,
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 033
1680
mi
from 02139
San Juan,
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #015
1252
mi
from 02139
Fort Myers, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #015
1252
mi
from 02139
Fort Myers, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 066
933
mi
from 02139
Smyrna, GA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 066
933
mi
from 02139
Smyrna, GA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 086
1054
mi
from 02139
Saint Charles, MO
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 086
1054
mi
from 02139
Saint Charles, MO
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
1965
mi
from 02139
Albuquerque, NM
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 020
1482
mi
from 02139
Bismarck, ND
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 020
1482
mi
from 02139
Bismarck, ND
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 045
1590
mi
from 02139
The Woodlands, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 045
1590
mi
from 02139
The Woodlands, TX
Click here to add this to my saved trials
Daily Weight Feedback for Wheelchair Users to Promote Weight Loss
Daily Self-weighing Feedback for Wheelchair Users to Promote Weight Loss Through Use of the E-scale
Status: Enrolling
Updated:  3/9/2018
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Daily Weight Feedback for Wheelchair Users to Promote Weight Loss
Daily Self-weighing Feedback for Wheelchair Users to Promote Weight Loss Through Use of the E-scale
Status: Enrolling
Updated: 3/9/2018
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Brain Imaging of rTMS Treatment for Depression
A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI
Status: Enrolling
Updated:  3/10/2018
Stanford University
2687
mi
from 02139
Palo Alto, CA
Brain Imaging of rTMS Treatment for Depression
A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI
Status: Enrolling
Updated: 3/10/2018
Stanford University
2687
mi
from 02139
Palo Alto, CA
Click here to add this to my saved trials
Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder
Status: Enrolling
Updated:  3/14/2018
Penn Center for Women's Behavioral Wellness
268
mi
from 02139
Philadelphia, PA
Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder
Status: Enrolling
Updated: 3/14/2018
Penn Center for Women's Behavioral Wellness
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Genecept Assay and Adverse Effects of Antidepressants
Genecept Assay and Adverse Effects of Antidepressants
Status: Enrolling
Updated:  3/14/2018
Thomas Jefferson University
268
mi
from 02139
Philadelphia, PA
Genecept Assay and Adverse Effects of Antidepressants
Genecept Assay and Adverse Effects of Antidepressants
Status: Enrolling
Updated: 3/14/2018
Thomas Jefferson University
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated:  3/15/2018
Centro de Salud Familiar La Fe CARE Center
2061
mi
from 02139
El Paso, TX
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated: 3/15/2018
Centro de Salud Familiar La Fe CARE Center
2061
mi
from 02139
El Paso, TX
Click here to add this to my saved trials
Improving Patient and Family Centered Care in Advanced Critical Illness
Improving Patient and Family Centered Care in Advanced Critical Illness
Status: Enrolling
Updated:  3/16/2018
University of Pittsburgh Medical Centers
477
mi
from 02139
Pittsburgh, PA
Improving Patient and Family Centered Care in Advanced Critical Illness
Improving Patient and Family Centered Care in Advanced Critical Illness
Status: Enrolling
Updated: 3/16/2018
University of Pittsburgh Medical Centers
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1048
mi
from 02139
Birmingham, AL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1048
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1254
mi
from 02139
Little Rock, AR
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1254
mi
from 02139
Little Rock, AR
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
2595
mi
from 02139
Beverly Hills, CA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
2595
mi
from 02139
Beverly Hills, CA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
2585
mi
from 02139
Cerritos, CA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
2585
mi
from 02139
Cerritos, CA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1763
mi
from 02139
Denver, CO
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1763
mi
from 02139
Denver, CO
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
114
mi
from 02139
Hamden, CT
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
114
mi
from 02139
Hamden, CT
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1249
mi
from 02139
North Miami, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1249
mi
from 02139
North Miami, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1112
mi
from 02139
Orlando, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1112
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1193
mi
from 02139
West Palm Beach, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1193
mi
from 02139
West Palm Beach, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
933
mi
from 02139
Smyrna, GA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
933
mi
from 02139
Smyrna, GA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1252
mi
from 02139
Overland Park, KA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1252
mi
from 02139
Overland Park, KA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
357
mi
from 02139
Baltimore, MD
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
357
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
254
mi
from 02139
Willingboro, NJ
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
254
mi
from 02139
Willingboro, NJ
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
2530
mi
from 02139
Portland, OR
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials